Assembly Biosciences Inc
ASMBHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET
20.18-2.19 (-9.79%)
2026-11-13 13:45 CET
Market cap
$410.88M
Revenue, TTM
67.01 USD m
Net income, TTM
-11.10 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.28
Price
ASMB against its 20, 50 and 200-day averagesPatternshover a marker to name it
49.2% under the 52-week high of 39.71 on 20 Nov 2025. 52-week low 19.20 on 5 Nov 2026. Last 15 sessions, 18.2% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 25
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
ASMB52-week range, 5% of the way up
19.2039.71
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 73 |
| IPO | Dec 17, 2010 |
| Beta | 1.22 |
| ATR, 14d | 1.25 |
| Rel volume | 0.00 |
| Short float | 23.69% |
| Insider own | 37.12% |
| Inst own | 67.56% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $410.88M |
| Enterprise Value | 98.83M |
| Income | -11.10M |
| Sales | 67.01M |
| Book / share | 14.67 |
| Cash / share | 15.43 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 73 |
| IPO | Dec 17, 2010 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 6.13 |
| Price / book | 1.38 |
| Price / cash | 1.31 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 1.47 |
| Quick Ratio | 13.99 |
| Current Ratio | 12.89 |
| Debt / equity | 0.01 |
| Long-term debt / equity | 0.01 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.28 |
|---|---|
| Earnings next year | -2.91 |
| Earnings next quarter | 0.51 |
| Earnings this year | -12.04% |
| Earnings next year | -372.42% |
| Earnings growth, 5 years | - |
| Past earnings growth | 71.29% 51.83% |
| Past sales growth | - -1.78% |
| Earnings vs last year | 98.69% |
| Sales vs last year | 80.18% |
| Earnings vs last quarter | -28.29% |
| Sales vs last quarter | -72.60% |
| Earnings | Nov 12 AMC |
| Surprise | -41.98% -67.42% |
Ownership
| Insiders own | 37.12% |
|---|---|
| Insider trades | -0.16% |
| Institutions own | 67.56% |
| Institution trades | 20.39% |
| Return on assets | -3.93% |
| Return on equity | -4.61% |
| Return on capital | -3.70% |
| Gross Margin | 100.00% |
| Operating margin | -31.83% |
| Profit Margin | -16.57% |
| 20-day average | -1.31% |
| 50-day average | -14.32% |
| 200-day average | -24.92% |
Technical
| Shares out | 20.37M |
|---|---|
| Shares floating | 12.80M |
| Short / float | 23.69% |
| Short ratio | 9.65 |
| Short interest | 3.03M |
| 52-week high | 39.71 -49.2% |
| 52-week low | 19.20 +5.1% |
| Volatility | 7.72% 5.44% |
| Average range | 1.25 |
| Strength index | 42.87 |
| Market sensitivity | 1.22 |
| Relative volume | 0.00 |
| Avg Volume | 314.13K |
| Volume | 0 |
Performance
| Perf Week | 0.90% |
|---|---|
| Perf Month | -1.70% |
| Perf Quarter | -38.76% |
| Perf Half Y | -33.40% |
| Perf YTD | -40.66% |
| Perf Year | -43.71% |
| Perf 3Y | 125.73% |
| Perf 5Y | -42.01% |
| Perf 10Y | -87.06% |
| Recommendation | 1.00 |
| Target Price | 51.20 |
| Prev Close | 20.18 |
| Price | 20.18 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 18| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 01, 2026 | Initiated | UBS | Buy | $52 | +157.7% |
| Sep 24, 2025 | Initiated | Citizens JMP | Mkt Outperform | $38 | +88.3% |
| Aug 18, 2025 | Resumed | H.C. Wainwright | Buy | $50 | +147.8% |
| Mar 25, 2025 | Initiated | Guggenheim | Buy | $31 | +53.6% |
| Sep 20, 2024 | Upgrade | Jefferies | Hold → Buy | $2 → $35 | +73.4% |
| Sep 13, 2021 | Initiated | H.C. Wainwright | Neutral | $3.50 | -82.7% |
| Sep 02, 2021 | Downgrade | William Blair | Outperform → Mkt Perform | ||
| Mar 23, 2021 | Downgrade | SVB Leerink | Outperform → Mkt Perform | ||
| Nov 06, 2020 | Downgrade | Jefferies | Buy → Hold | $30 → $10 | -50.4% |
| Oct 19, 2020 | Initiated | Truist | Buy | $55 | +172.5% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ABUS | Arbutus Biopharma Corp | 629.47M |
| ENTA | Enanta Pharmaceuticals Inc | 326.20M |
| VIR | Vir Biotechnology Inc | 1.74B |
| ALGS | Aligos Therapeutics Inc | 13.96M |
| AVIR | Atea Pharmaceuticals Inc | 338.08M |
| ARWR | Arrowhead Pharmaceuticals Inc | 6.60B |
| COCP | Cocrystal Pharma Inc | 19.07M |
| TRAW | Traws Pharma Inc | 4.15M |
| INO | Inovio Pharmaceuticals Inc | 273.47M |
| NNVC | NanoViricides Inc | 34.46M |
Insider trading
10 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | Nov 02 '26 | Sale | 19.62 | 727 | 14,261 | 17,673 | Nov 03 04:50 PM |
| White Nicole S | Chief Manufacturing Officer | Nov 02 '26 | Sale | 19.62 | 2,593 | 50,864 | 59,257 | Nov 03 04:45 PM |
| Gaggar Anuj | Chief Medical Officer | Nov 02 '26 | Sale | 19.62 | 2,593 | 50,864 | 53,800 | Nov 03 04:35 PM |
| Okazaki Jason A | CEO and President | Nov 02 '26 | Sale | 19.62 | 6,202 | 121,658 | 195,532 | Nov 03 04:30 PM |
| Nicole S. White | Officer | Nov 02 '26 | Proposed Sale | 19.62 | 2,593 | 50,864 | Nov 02 06:40 PM | |
| Anuj Gaggar | Officer | Nov 02 '26 | Proposed Sale | 19.62 | 2,593 | 50,864 | Nov 02 06:35 PM | |
| Jason A. Okazaki | Officer | Nov 02 '26 | Proposed Sale | 19.62 | 6,202 | 121,658 | Nov 02 06:30 PM | |
| Bjorkquist Jeanette M | PFO and PAO | Jun 17 '26 | Sale | 23.25 | 29 | 674 | 14,560 | Jun 18 04:05 PM |
| Bjorkquist Jeanette M | PFO and PAO | Mar 30 '26 | Sale | 26.69 | 328 | 8,755 | 11,089 | Mar 31 04:25 PM |
| White Nicole S | Chief Manufacturing Officer | Mar 30 '26 | Sale | 26.69 | 197 | 5,258 | 37,477 | Mar 31 04:20 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
News
latest 14 of 200- Assembly Biosciences: Q3 Earnings Snapshot (Associated Press) -9.79%
- Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates (GlobeNewswire)
- Assembly Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
- Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus (GlobeNewswire)
- Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting 2026 (GlobeNewswire)
- Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference (GlobeNewswire) -7.33%
- Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program (GlobeNewswire) -6.83%
- Assembly Biosciences: Q2 Earnings Snapshot (Associated Press) +10.68% +10.02%
- Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates (GlobeNewswire)
- Assembly Biosciences Announces Upcoming Investor Conference Presentations (GlobeNewswire)
- Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
- Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.94%
- Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases (GlobeNewswire)
- Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.930 missed -0.655, from -0.720 a year earlier. Sales 2.96 missed 9.07, from 10.79 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 16:30 | -0.930 | -0.655 | -0.930 | 2.96 | 9.07 | EPS +42.0% · sales -67.4% | vs 2025Q3, year-ago quarter · EPS +29.2% · sales -72.6% | 4 | - |
| 2026Q2ended 2026-06-30 | 2026-08-13 16:30 | -0.200 | -0.724 | -0.205 | 13.37 | 8.60 | EPS -72.4% · sales +55.5% | vs 2025Q2, year-ago quarter · EPS -85.0% · sales +38.9% | 4 EPS · 3 sales | Open +0.43% vs SPY +0.08%. Close +10.02% vs SPY -0.20% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -0.540 | -0.650 | -0.537 | 8.21 | 9.27 | EPS -16.9% · sales -11.4% | vs 2025Q1, year-ago quarter · EPS -53.8% · sales -12.8% | 4 EPS · 3 sales | Open -1.26% vs SPY +0.46%. Close -3.85% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-03-19 16:30 | 1.393 | -0.856 | 1.393 | 42.46 | 7.42 | EPS -262.7% · sales +472.2% | vs 2024Q4, year-ago quarter · EPS -190.4% · sales +476.9% | 4 | Open +9.52% vs SPY -0.50%. Close +3.45% vs SPY -1.70% |
| 2025Q3ended 2025-09-30 | 2025-11-10 16:30 | -0.720 | -0.821 | -0.725 | 10.79 | 7.46 | EPS -12.3% · sales +44.6% | vs 2024Q3, year-ago quarter · EPS -52.3% · sales +57.6% | 5 | Open +0.12% vs SPY -0.22%. Close +3.31% vs SPY +0.23% |
| 2025Q2ended 2025-06-30 | 2025-08-06 16:30 | -1.330 | -1.730 | -1.332 | 9.63 | 5.30 | EPS -23.1% · sales +81.7% | vs 2024Q2, year-ago quarter · EPS -32.8% · sales +12.8% | 2 | Open -1.54% vs SPY +0.55%. Close +9.21% vs SPY -0.08% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -1.170 | -1.600 | -1.175 | 9.42 | 7.41 | EPS -26.9% · sales +27.0% | vs 2024Q1, year-ago quarter · EPS -29.5% · sales +62.8% | 2 | Open +2.92% vs SPY +0.25%. Close +4.97% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-20 16:30 | -1.540 | -1.795 | -1.570 | 7.36 | 3.55 | EPS -14.2% · sales +107.3% | vs 2023Q4, year-ago quarter · EPS -17.2% · sales +2.2% | 2 | Open +2.90% vs SPY -1.10%. Close +2.99% vs SPY -0.27% |
| 2024Q3ended 2024-09-30 | 2024-11-07 16:30 | -1.510 | -2.303 | -1.514 | 6.85 | 5.77 | EPS -34.4% · sales +18.7% | vs 2023Q3, year-ago quarter · EPS -53.4% · sales - | 3 | Open -2.11% vs SPY +0.09%. Close -4.11% vs SPY +0.43% |
| 2024Q2ended 2024-06-30 | 2024-08-08 16:30 | -1.980 | -2.230 | -1.976 | 8.53 | 6.00 | EPS -11.2% · sales +42.2% | vs 2023Q2, year-ago quarter · EPS -48.4% · sales - | 1 | Open -6.65% vs SPY -0.16%. Close -2.84% vs SPY +0.44% |
| 2024Q1ended 2024-03-31 | 2024-05-08 16:30 | -1.660 | -3.230 | -1.655 | 5.79 | 0.00 | EPS -48.6% · sales - | vs 2023Q1, year-ago quarter · EPS -62.6% · sales - | 1 | Open +2.72% vs SPY +0.04%. Close +1.25% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-03-28 16:30 | -1.860 | -2.820 | -1.999 | 7.20 | 0.00 | EPS -34.0% · sales - | vs 2022Q4, year-ago quarter · EPS -65.6% · sales - | 2 | Open 0.00% vs SPY +0.15%. Close -3.01% vs SPY -0.17% |
| 2023Q3ended 2023-09-30 | 2023-11-08 16:30 | -3.240 | -2.820 | -3.292 | 0.00 | 0.00 | EPS +14.9% · sales - | vs 2022Q3, year-ago quarter · EPS -43.7% · sales - | 2 | - |
| 2023Q2ended 2023-06-30 | 2023-08-09 16:30 | -3.840 | -3.360 | -3.880 | 0.00 | 0.00 | EPS +14.3% · sales - | vs 2022Q2, year-ago quarter · EPS -37.3% · sales - | 3 | - |
| 2023Q1ended 2023-03-31 | 2023-05-04 16:30 | -4.440 | -4.160 | -4.458 | 0.00 | 0.00 | EPS +6.7% · sales - | vs 2022Q1, year-ago quarter · EPS -22.9% · sales - | 3 | - |
| 2022Q4ended 2022-12-31 | 2023-03-22 16:30 | -5.400 | -4.760 | -5.508 | 0.00 | 0.00 | EPS +13.4% · sales - | vs 2021Q4, year-ago quarter · EPS -66.7% · sales - | 3 EPS · 2 sales | - |
Annual earnings
2025FY EPS -0.550 beat -3.750, from -6.690 a year earlier. Sales 72.30 beat 37.14, from 28.52 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -1.520 | - | - | 123.13 | - |
| 2029FYestimate | - | -3.093 | - | - | 27.30 | - |
| 2028FYestimate | - | -1.947 | - | - | 68.20 | - |
| 2027FYestimate | - | -2.911 | - | - | 42.65 | - |
| 2026FYestimate | - | -0.616 | - | - | 63.01 | - |
| 2025FY | -0.550 | -3.750 | -0.550 | 72.30 | 37.14 | - |
| 2024FY | -6.690 | -6.755 | -6.691 | 28.52 | 24.60 | - |
| 2023FY | -13.380 | -14.220 | -13.376 | 7.16 | 0.00 | - |
| 2022FY | -23.040 | -21.120 | -23.076 | 0.00 | 0.00 | - |
| 2021FY | -36.000 | -25.200 | -36.004 | 6.25 | 7.41 | - |
| 2020FY | -21.000 | -18.672 | -21.052 | 79.11 | 82.01 | - |
| 2019FY | -44.640 | -44.940 | -44.618 | 15.96 | 14.81 | - |
| 2018FY | -47.760 | -46.410 | -47.760 | 14.80 | 14.88 | - |
| 2017FY | -28.920 | -35.310 | -28.920 | 9.02 | 7.09 | - |
| 2016FY | -30.840 | -30.840 | -30.840 | 0.00 | 0.00 | - |
| 2015FY | -21.720 | - | -21.720 | - | - | - |
| 2014FY | -40.800 | -40.440 | -40.800 | - | - | - |
| 2013FY | -60.000 | -59.400 | -60.000 | - | 0.00 | - |
| 2012FY | -116.4 | -118.8 | -116.4 | 0.00 | 0.00 | - |
| 2011FY | -214.2 | -181.5 | -214.2 | 0.00 | 0.00 | - |
| 2010FY | -1,029 | 0.000 | - | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 2.96, from 10.79 a year earlier. Operating margin -790.88%, from -100.83% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.62 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-13 | -0.62 | +1.3% |
| 2026Q4 | E | per share | 2026-11-13 | 0.51 | +5.8% |
| 2026FY | R | per share | 2026-11-13 | 0.31 | -4.1% |
| 2026Q4 | R | per share | 2026-11-13 | 1.36 | +3.5% |
| 2026FY | S | per share | 2026-11-13 | 63.01 | -0.7% |
| 2026Q4 | S | per share | 2026-11-13 | 43.14 | 0.0% |
| 2026Q3 | E | per share | 2026-11-11 | -0.66 | 0.0% |
| 2026Q3 | R | per share | 2026-10-31 | -0.51 | 0.0% |
| 2026Q3 | S | per share | 2026-10-31 | 9.07 | 0.0% |
| 2026Q2 | E | per share | 2026-08-10 | -0.72 | 0.0% |
| 2026Q2 | R | per share | 2026-07-26 | -0.80 | 0.0% |
| 2026Q2 | S | per share | 2026-06-08 | 8.60 | 0.0% |
| 2026Q1 | E | per share | 2026-04-01 | -0.65 | -15.6% |
| 2026Q1 | S | per share | 2026-04-01 | 9.27 | +7.7% |
| 2026Q1 | R | per share | 2026-03-25 | -0.71 | +2.9% |
| 2025FY | E | per share | 2026-03-18 | -3.83 | 0.0% |
| 2025Q4 | E | per share | 2026-03-18 | -0.95 | 0.0% |
| 2025Q4 | S | per share | 2026-03-18 | 9.55 | 0.0% |
| 2025FY | S | per share | 2026-03-01 | 37.14 | 0.0% |
| 2025FY | R | per share | 2026-01-26 | -3.30 | 0.0% |
| 2025Q4 | R | per share | 2025-11-15 | -0.51 | -39.3% |
| 2025Q3 | E | per share | 2025-10-29 | -0.82 | 0.0% |
| 2025Q3 | S | per share | 2025-10-11 | 7.46 | 0.0% |
| 2025Q3 | R | per share | 2025-08-15 | -0.82 | -28.1% |
| 2025Q2 | E | per share | 2025-07-23 | -1.73 | 0.0% |
| 2025Q2 | S | per share | 2025-07-23 | 5.30 | 0.0% |
| 2025Q1 | E | per share | 2025-03-24 | -1.60 | +3.9% |
| 2025Q1 | S | per share | 2025-03-24 | 7.41 | -4.5% |
| 2024FY | E | per share | 2025-02-02 | -6.76 | 0.0% |
| 2024Q4 | E | per share | 2025-02-02 | -1.80 | 0.0% |
| 2024FY | S | per share | 2025-02-02 | 24.60 | 0.0% |
| 2024Q4 | S | per share | 2025-01-22 | 3.55 | 0.0% |
| 2024Q4 | R | per share | 2024-11-08 | -2.33 | 0.0% |
| 2025Q1 | R | per share | 2024-11-08 | -2.47 | 0.0% |
| 2025Q2 | R | per share | 2024-11-08 | -1.63 | 0.0% |
| 2024Q3 | E | per share | 2024-10-23 | -2.30 | 0.0% |
| 2024Q3 | S | per share | 2024-10-23 | 5.77 | 0.0% |
| 2024FY | R | per share | 2024-09-18 | -8.22 | -15.4% |
| 2024Q3 | R | per share | 2024-09-18 | -2.19 | - |
| 2024Q2 | E | per share | 2024-07-23 | -2.23 | 0.0% |
| 2024Q2 | S | per share | 2024-07-23 | 6.00 | 0.0% |
| 2024Q1 | E | per share | 2024-03-29 | -3.23 | -0.3% |
| 2024Q1 | S | per share | 2024-03-29 | 0.00 | - |
| 2023FY | E | per share | 2024-01-28 | -14.22 | 0.0% |
| 2023FY | S | per share | 2023-09-25 | 0.00 | - |
| 2023FY | R | per share | 2023-08-15 | -14.88 | -0.8% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -28.92 | -47.76 | -44.618 | -21.052 | -36.004 | -23.076 | -13.376 | -6.691 | -0.546 | -0.2786 | - |
| Sales USD millions | 9 | 15 | 16 | 79 | 6 | 0 | 7 | 29 | 72 | 67 | - |
| Shares million shares | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 7 | 16 | - | 20 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -1.514 | -1.57 | -1.175 | -1.332 | -0.725 | 1.393 | -0.537 | -0.205 | -0.93 |
| Sales USD millions | 7 | 7 | 9 | 10 | 11 | 42 | 8 | 13 | 3 |
| Shares million shares | 6 | 7 | 8 | 8 | 16 | 16 | 16 | 20 | 20 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 67.01 | 72.30+153.5% | 28.52+298.3% | 7.16 | 0.00-100.0% | 6.25-92.1% | 79.11+395.7% | 15.96+7.8% | 14.80 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.130.0% | 0.13-71.1% | 0.45-10.0% | 0.50+6.4% | 0.47 | - | - | - |
| Gross Profit | 67.01 | 72.17+154.2% | 28.39+323.1% | 6.71 | -0.50-108.6% | 5.79 | - | - | - |
| Selling, General and Administrative Excl. Other | 88.26 | 84.29+14.2% | 73.81+3.4% | 71.36-22.9% | 92.52-5.8% | 98.19-31.4% | 143.19+23.4% | 116.08+8.6% | 106.90 |
| Research and Development | 67.22 | 64.68+15.9% | 55.80+14.1% | 48.90-29.2% | 69.11-1.5% | 70.15-34.3% | 106.82+25.1% | 85.36+17.3% | 72.74 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -21.33 | -12.12 | -45.42 | -64.65 | -93.02 | -92.40 | -64.78 | -100.61 | -92.73 |
| Interest Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | - | 0.00 | 0.00 | 0.00-100.0% | 1.10-97.3% | 40.29 | 0.00-100.0% | 2.10 | - |
| Net Income Before Taxes | -11.10 | -6.12 | -39.85 | -61.20 | -93.09 | -132.39 | -62.15 | -98.41 | -89.65 |
| Income Taxes | 0.00 | 0.00-100.0% | 0.33+1000.0% | 0.03 | 0.00 | -2.53 | 0.00 | -0.77-170.0% | 1.10 |
| Consolidated Net Income | -11.10 | -6.12 | -40.18 | -61.23 | -93.09 | -129.85 | -62.15 | -97.63 | -90.75 |
| Net Income From Continuing Operations | -11.10 | -6.12 | -40.18 | -61.23 | -93.09 | -129.85 | -62.15 | -97.63 | -90.75 |
| Net Income | -11.10 | -6.12 | -40.18 | -61.23 | -93.09 | -129.85 | -62.15 | -97.63 | -90.75 |
| EPS (Recurring) per share | -0.51 | -0.55 | -6.69 | -13.38 | -22.89 | -28.18 | -21.05 | -43.95 | -47.76 |
| EPS (Basic, Before Extraordinaries) per share | -0.28 | -0.55 | -6.69 | -13.38 | -23.08 | -36.00 | -21.05 | -44.62 | -47.76 |
| EPS (Diluted) per share | -0.28 | -0.55 | -6.69 | -13.38 | -23.08 | -36.00 | -21.05 | -44.62 | -47.76 |
| EBITDA | - | -11.99 | -45.29 | -64.20 | -92.52 | -91.93 | -64.08 | -100.12 | -92.09 |
| Non-Operating Income (Expense) | 10.23 | 6.00+7.7% | 5.57+61.4% | 3.45+238.2% | 1.02+240.0% | 0.30-88.5% | 2.62-39.1% | 4.30+39.6% | 3.08 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 3.69+50.0% | 2.46-52.0% | 5.12-22.3% | 6.59+72.5% | 3.82-82.5% | 21.85+45.6% | 15.01-33.3% | 22.50 |
| Price To Sales Ratio ratio | - | 5.27 | 3.32 | 6.29 | - | 16.12 | 2.71 | 33.66 | 34.84 |
| Gross Margin % | 100.00 | 99.82 | 99.55 | 93.72 | - | 92.55 | - | - | - |
| Operating Margin % | -31.83 | -16.76 | -159.26 | -902.50 | - | -1,477.42 | -81.89 | -630.29 | -626.42 |
| Net Margin % | -16.57 | -8.47 | -140.87 | -854.78 | - | -2,076.35 | -78.57 | -611.63 | -613.02 |
| Shares Outstanding million shares | 20.37 | 15.86+112.6% | 7.46+36.1% | 5.48+34.6% | 4.07+1.5% | 4.01+41.2% | 2.84+4.8% | 2.71+27.8% | 2.12 |
| Market Capitalization | 410.88 | 410.88+309.7% | 100.30+132.4% | 43.15-31.5% | 63.03-43.8% | 112.12-45.5% | 205.86-69.1% | 666.14+15.5% | 576.71 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.96-72.6% | 13.37+38.8% | 8.21-12.8% | 42.47+477.0% | 10.79+57.7% | 9.63+12.9% | 9.42+62.7% | 7.36+2.8% |
| Cost of Goods Sold Incl. D&A | 0.00-100.0% | 0.02-33.3% | 0.030.0% | 0.030.0% | 0.030.0% | 0.030.0% | 0.030.0% | 0.03-62.5% |
| Gross Profit | 2.96-72.5% | 13.35+39.2% | 8.19-12.8% | 42.44+479.0% | 10.76+58.0% | 9.59+12.8% | 9.39+63.3% | 7.33+3.5% |
| Selling, General and Administrative Excl. Other | 26.37+21.9% | 19.70-4.8% | 19.56+1.2% | 22.64+20.0% | 21.64+21.8% | 20.690.0% | 19.33+17.3% | 18.86-3.9% |
| Research and Development | 20.23+22.2% | 14.90-7.4% | 14.87+0.3% | 17.22+20.8% | 16.55+22.4% | 16.09-1.0% | 14.82+24.7% | 14.25+29.4% |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.41 | -6.34 | -11.37 | 19.80 | -10.88 | -11.09 | -9.94 | -11.53 |
| Interest Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -20.26 | -3.86 | -9.08 | 22.09 | -9.20 | -10.20 | -8.82 | -10.41 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | -0.08-366.7% |
| Consolidated Net Income | -20.26 | -3.86 | -9.08 | 22.09 | -9.20 | -10.20 | -8.82 | -10.34 |
| Net Income From Continuing Operations | -20.26 | -3.86 | -9.08 | 22.09 | -9.20 | -10.20 | -8.82 | -10.34 |
| Net Income | -20.26 | -3.86 | -9.08 | 22.09 | -9.20 | -10.20 | -8.82 | -10.34 |
| EPS (Recurring) per share | -0.93 | -0.20 | -0.54 | 1.39 | -0.72 | -1.33 | -1.17 | -1.57 |
| EPS (Basic, Before Extraordinaries) per share | -0.93 | -0.20 | -0.54 | 1.39 | -0.72 | -1.33 | -1.17 | -1.57 |
| EPS (Diluted) per share | -0.93 | -0.20 | -0.54 | 1.39 | -0.72 | -1.33 | -1.17 | -1.57 |
| EBITDA | - | -6.32 | -11.34 | 19.83 | -10.85 | -11.06 | -9.91 | -11.50 |
| Non-Operating Income (Expense) | 3.16+87.0% | 2.49+176.7% | 2.29+104.5% | 2.29+104.5% | 1.69+26.1% | 0.90-38.4% | 1.12-32.1% | 1.12-30.9% |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 2.42+191.6% | 1.12+57.7% | 0.48-18.6% | 1.67+108.7% | 0.83+25.8% | 0.71-4.1% | 0.59-38.5% |
| Price To Sales Ratio ratio | - | 6.92 | 6.60 | 7.46 | 8.73 | 4.17 | 2.23 | 3.64 |
| Gross Margin % | 100.00 | 99.85 | 99.68 | 99.92 | 99.70 | 99.67 | 99.65 | 99.57 |
| Operating Margin % | -792.12 | -47.44 | -138.44 | 46.62 | -100.87 | -115.24 | -105.54 | -156.75 |
| Net Margin % | -685.25 | -28.84 | -110.54 | 52.01 | -85.23 | -105.94 | -93.62 | -140.48 |
| Shares Outstanding million shares | 20.37+28.8% | 19.85+158.8% | 15.89+108.5% | 15.86+112.6% | 15.82+149.1% | 7.67+20.8% | 7.62+39.1% | 7.46+36.1% |
| Market Capitalization | 410.88+3.1% | 544.58+293.5% | 440.19+513.7% | 537.94+436.3% | 398.34+314.6% | 138.39+63.6% | 71.73-1.6% | 100.30+132.4% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 248.11+121.4% | 112.08-14.0% | 130.25+42.2% | 91.61-37.5% | 146.63-32.2% | 216.41-21.0% | 274.04+25.7% | 218.08+81.8% | 119.95 |
| Short Term Receivables | 2.47+517.5% | 0.40+900.0% | 0.04-95.7% | 0.94+176.5% | 0.34-72.4% | 1.23-63.5% | 3.37+38.7% | 2.43+7.0% | 2.27 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.97+31.5% | 3.02-13.7% | 3.50-20.6% | 4.41-39.1% | 7.24+5.7% | 6.85+27.8% | 5.36+169.3% | 1.99+121.1% | 0.90 |
| Total Current Assets | 254.55+120.4% | 115.50-13.7% | 133.79+38.0% | 96.97-37.1% | 154.20-31.3% | 224.49-20.6% | 282.78+27.1% | 222.50+80.7% | 123.12 |
| Net Property, Plant & Equipment | 2.73-18.5% | 3.35+23.2% | 2.72-31.0% | 3.94-45.1% | 7.18-33.1% | 10.73-22.2% | 13.80+2364.3% | 0.56-34.9% | 0.86 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 27.97 | 0.00 | 0.00 | 0.00-100.0% | 3.35 |
| Intangible Assets | - | - | - | - | 0.00-100.0% | 41.640.0% | 41.640.0% | 41.640.0% | 41.64 |
| Deferred Tax Assets | 0.70-13.6% | 0.81+24.6% | 0.65-19.8% | 0.81-47.4% | 1.54-78.8% | 7.26-9.0% | 7.98 | - | - |
| Other Assets | 0.310.0% | 0.310.0% | 0.31-65.2% | 0.89-47.6% | 1.70-73.4% | 6.39+280.4% | 1.68-49.9% | 3.35+885.3% | 0.34 |
| Total Assets | 258.29+115.3% | 119.97-12.7% | 137.47+34.0% | 102.61-46.7% | 192.60-33.7% | 290.51-16.5% | 347.89+29.8% | 268.05+58.3% | 169.30 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.57+23.9% | 0.46-62.3% | 1.22-63.7% | 3.36+6.7% | 3.15-7.4% | 3.40+6.6% | 3.19 | 0.00 | 0.00 |
| Accounts Payable | 1.17+101.7% | 0.58+26.1% | 0.46-81.5% | 2.49-6.4% | 2.66-42.2% | 4.60+165.9% | 1.73-53.1% | 3.69+74.1% | 2.12 |
| Other Current Liabilities | 47.04+0.6% | 46.76+24.6% | 37.54+259.6% | 10.44+1.8% | 10.26-37.6% | 16.43-15.8% | 19.52+32.1% | 14.78+30.0% | 11.37 |
| Total Current Liabilities | 48.78+2.1% | 47.80+21.8% | 39.23+140.7% | 16.30+1.4% | 16.07-34.2% | 24.430.0% | 24.44+32.3% | 18.47+36.9% | 13.49 |
| Long Term Debt | 2.06-21.7% | 2.63+134.8% | 1.12+1020.0% | 0.10-97.0% | 3.33-50.4% | 6.72-26.0% | 9.08 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 0.70-13.6% | 0.81+24.6% | 0.65-19.8% | 0.81-47.4% | 1.54-84.3% | 9.79-6.9% | 10.51+223.4% | 3.25+51.9% | 2.14 |
| Other Liabilities | 0.00-100.0% | 35.38-36.1% | 55.38+1928.6% | 2.730.0% | 2.73-69.6% | 8.99-70.7% | 30.64-14.1% | 35.67-12.1% | 40.56 |
| Total Liabilities | 51.54-40.5% | 86.61-10.1% | 96.37+383.3% | 19.94-15.8% | 23.68-52.6% | 49.93-33.1% | 74.67+30.1% | 57.39+2.2% | 56.18 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 206.75+519.8% | 33.36-18.8% | 41.10-50.3% | 82.66-51.1% | 168.93-29.8% | 240.58-11.9% | 273.22+29.7% | 210.65+86.2% | 113.12 |
| Total Shareholders Equity | 206.75+519.8% | 33.36-18.8% | 41.10-50.3% | 82.66-51.1% | 168.93-29.8% | 240.58-11.9% | 273.22+29.7% | 210.65+86.2% | 113.12 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 206.75+519.8% | 33.36-18.8% | 41.10-50.3% | 82.66-51.1% | 168.93-29.8% | 240.58-11.9% | 273.22+29.7% | 210.65+86.2% | 113.12 |
| Total Liabilities & Stockholders Equity | 258.29+115.3% | 119.97-12.7% | 137.47+34.0% | 102.61-46.7% | 192.60-33.7% | 290.51-16.5% | 347.89+29.8% | 268.05+58.3% | 169.30 |
| Book Value Per Share per share | 13.04+191.7% | 4.47-40.4% | 7.50-63.0% | 20.29-51.8% | 42.13-50.3% | 84.84-15.7% | 100.70+1.6% | 99.15+47.1% | 67.41 |
| Tangible Book Value Per Share per share | 13.04+191.7% | 4.47-40.4% | 7.50-63.0% | 20.29-51.8% | 42.13-40.0% | 70.16-17.8% | 85.35+7.3% | 79.55+86.7% | 42.60 |
| Full-Time Employees people | 730.0% | 73+12.3% | 65-4.4% | 68-33.3% | 102-26.6% | 139+20.9% | 115+21.1% | 95+20.3% | 79 |
| Price to Book Ratio ratio | 1.31 | 3.86 | 1.03 | 0.62 | 0.66 | 0.86 | 2.44 | 2.74 | 16.69 |
| Return on Assets % | -3.24 | -31.21 | -51.01 | -63.07 | -53.76 | -19.47 | -31.70 | -41.50 | -32.02 |
| Return on Equity % | -5.10 | -107.92 | -98.95 | -74.00 | -63.42 | -24.19 | -40.36 | -56.06 | -44.36 |
| Return on Invested Capital % | -2.93 | -111.64 | -145.02 | -112.48 | -75.39 | -25.13 | -34.59 | -43.08 | -37.84 |
| Quick Ratio ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 |
| Current Ratio ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -6.12 | -40.18 | -61.23 | -93.09 | -129.85 | -62.15 | -97.63 | -90.75 |
| Depreciation | - | 0.130.0% | 0.13-71.1% | 0.45-10.0% | 0.50+6.4% | 0.47-31.9% | 0.69+40.8% | 0.49-23.4% | 0.64 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | -2.53 | 0.00 | -0.77-170.0% | 1.10 |
| Other Funds (Non Cash) | - | 3.18+261.4% | 0.88-87.7% | 7.18-30.0% | 10.25-79.5% | 49.92+73.3% | 28.81+23.3% | 23.37-17.3% | 28.26 |
| Funds from Operations | - | -2.81 | -39.17 | -53.60 | -82.34 | -82.00 | -32.65 | -74.54 | -60.75 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -38.28 | -11.95-115.7% | 76.34 | -2.12 | -11.40 | -30.31 | -9.53 | -4.21 |
| Cash from Operating Activities | - | -41.09 | -51.12-324.8% | 22.74 | -84.46 | -93.40 | -62.96 | -84.07 | -64.96 |
| Capital Expenditures | - | -0.07 | -0.03 | -0.26 | -0.10 | -3.10 | -2.22 | -1.55 | -0.34 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00-100.0% | 0.02 | 0.00-100.0% | 0.86 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | - | -113.40-382.1% | 40.20 | -68.91-175.9% | 90.74+215.6% | 28.75-59.1% | 70.29 | -48.76 | -135.06 |
| Purchase of Investments | - | -229.83 | -90.50 | -133.92 | -27.58 | -160.45 | -193.19 | -281.33 | -183.94 |
| Sale Or Maturity of Investments | - | 116.43-10.9% | 130.70+101.0% | 65.02-45.1% | 118.33-37.5% | 189.20-28.2% | 263.48+13.3% | 232.57+375.8% | 48.88 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | -113.47-382.5% | 40.17 | -69.14-176.3% | 90.64+241.8% | 26.52-61.0% | 68.07 | -50.32 | -135.40 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 174.67+493.1% | 29.45+113.1% | 13.82+2165.6% | 0.61-98.9% | 53.06+598.2% | 7.60-94.6% | 139.65-12.6% | 159.79 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 174.67+493.1% | 29.45+113.1% | 13.82+2165.6% | 0.61-98.9% | 53.06+598.2% | 7.60-94.6% | 139.65-12.6% | 159.79 |
| Proceedsfrom Stock Options | - | 123.60 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 5.45-96.0% | 135.41-13.1% | 155.83 |
| Issuance or Reduction of Debt, Net | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | - | 174.67+493.1% | 29.45+113.1% | 13.82+2165.6% | 0.61-98.9% | 53.06+598.2% | 7.60-94.6% | 139.65-12.6% | 159.79 |
| Net Change in Cash | - | 20.11+8.7% | 18.50 | -32.58-579.8% | 6.79 | -13.82-208.7% | 12.71+141.6% | 5.26 | -40.56 |
| Free Cash Flow | - | -41.16 | -51.15-327.4% | 22.49 | -84.56 | -96.49 | -63.43 | -85.62 | -65.30 |
| Price to Free Cash Flow ratio | - | - | - | 2.00 | - | - | - | - | - |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 314.26+35.1% | 320.36+327.3% | 226.60+148.9% | 248.11+121.4% | 232.56+144.9% | 74.98-31.3% | 91.03-19.4% | 112.08-14.0% |
| Short Term Receivables | 0.58-69.6% | 2.92+873.3% | 1.45+262.5% | 2.47+517.5% | 1.91+377.5% | 0.30-25.0% | 0.40+17.6% | 0.40+900.0% |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 6.32+170.1% | 4.70+114.6% | 4.56+11.2% | 3.97+31.5% | 2.34-18.2% | 2.19-33.8% | 4.10+6.5% | 3.02-13.7% |
| Total Current Assets | 321.16+35.6% | 327.98+323.4% | 232.61+143.5% | 254.55+120.4% | 236.81+141.1% | 77.47-31.4% | 95.53-18.5% | 115.50-13.7% |
| Net Property, Plant & Equipment | 2.37-17.4% | 2.54-15.3% | 2.58-18.9% | 2.73-18.5% | 2.87+64.9% | 3.00+44.2% | 3.18+32.5% | 3.35+23.2% |
| Total Investments and Advances | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | - | 0.70-13.6% | - | - | - | 0.81+24.6% |
| Other Assets | 1.75+464.5% | 0.310.0% | 0.310.0% | 0.310.0% | 0.310.0% | 0.310.0% | 0.310.0% | 0.310.0% |
| Total Assets | 325.29+35.5% | 330.83+309.5% | 235.51+137.8% | 258.29+115.3% | 240.00+139.4% | 80.78-30.0% | 99.02-17.4% | 119.97-12.7% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.64+16.4% | 0.61+15.1% | 0.59+11.3% | 0.57+23.9% | 0.55-58.6% | 0.53-58.9% | 0.53-53.9% | 0.46-62.3% |
| Accounts Payable | 3.18+89.3% | 1.18+59.5% | 1.13+28.4% | 1.17+101.7% | 1.68+26.3% | 0.74-7.5% | 0.88+20.5% | 0.58+26.1% |
| Other Current Liabilities | 21.10-58.7% | 21.65-53.0% | 33.28-26.4% | 47.04+0.6% | 51.15+31.3% | 46.02+17.5% | 45.23+22.6% | 46.76+24.6% |
| Total Current Liabilities | 24.92-53.3% | 23.45-50.4% | 35.00-24.9% | 48.78+2.1% | 53.38+28.2% | 47.29+14.6% | 46.63+20.3% | 47.80+21.8% |
| Long Term Debt | 1.57-29.0% | 1.74-26.0% | 1.90-23.7% | 2.06-21.7% | 2.21+1909.1% | 2.35+422.2% | 2.49+215.2% | 2.63+134.8% |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 0.70-13.6% | - | - | - | 0.81+24.6% |
| Other Liabilities | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 1.72-94.7% | 13.04-66.5% | 22.76-52.3% | 35.38-36.1% |
| Total Liabilities | 26.49-53.8% | 25.18-59.8% | 36.90-48.7% | 51.54-40.5% | 57.30-22.8% | 62.68-22.3% | 71.88-17.6% | 86.61-10.1% |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 298.79+63.6% | 305.65+1588.7% | 198.61+632.1% | 206.75+519.8% | 182.69+602.7% | 18.10-47.8% | 27.13-16.8% | 33.36-18.8% |
| Total Shareholders Equity | 298.79+63.6% | 305.65+1588.7% | 198.61+632.1% | 206.75+519.8% | 182.69+602.7% | 18.10-47.8% | 27.13-16.8% | 33.36-18.8% |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 298.79+63.6% | 305.65+1588.7% | 198.61+632.1% | 206.75+519.8% | 182.69+602.7% | 18.10-47.8% | 27.13-16.8% | 33.36-18.8% |
| Total Liabilities & Stockholders Equity | 325.29+35.5% | 330.83+309.5% | 235.51+137.8% | 258.29+115.3% | 240.00+139.4% | 80.78-30.0% | 99.02-17.4% | 119.97-12.7% |
| Book Value Per Share per share | 14.67+27.0% | 15.40+552.5% | 12.50+251.1% | 13.04+191.7% | 11.55+182.4% | 2.36-56.9% | 3.56-40.2% | 4.47-40.4% |
| Tangible Book Value Per Share per share | 14.67+27.0% | 15.40+552.5% | 12.50+251.1% | 13.04+191.7% | 11.55+182.4% | 2.36-56.9% | 3.56-40.2% | 4.47-40.4% |
| Full-Time Employees people | - | - | - | 730.0% | - | - | - | 73+12.3% |
| Price to Book Ratio ratio | 1.31 | 2.20 | 2.13 | 2.94 | 10.85 | 5.09 | 2.14 | 3.86 |
| Return on Assets % | -3.93 | -0.02 | -3.82 | -3.24 | -22.66 | -39.74 | -36.47 | -31.21 |
| Return on Equity % | -4.61 | -0.03 | -5.66 | -5.10 | -36.94 | -147.64 | -133.65 | -107.92 |
| Return on Invested Capital % | -6.74 | -1.25 | -4.53 | 10.58 | -4.97 | -49.87 | -29.77 | -28.72 |
| Quick Ratio ratio | - | 13.99 | 6.65 | 5.22 | 4.44 | 1.64 | 2.05 | 2.42 |
| Current Ratio ratio | 12.89 | 13.99 | 6.65 | 5.22 | 4.44 | 1.64 | 2.05 | 2.42 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | - | -3.86 | -9.08 | 22.09 | -9.20 | -10.20 | -8.82 | -10.34 |
| Depreciation | - | 0.02-33.3% | 0.030.0% | 0.030.0% | 0.030.0% | 0.030.0% | 0.030.0% | 0.03-62.5% |
| Other Funds (Non Cash) | - | 1.85+176.1% | 0.53+26.2% | 0.83+62.7% | 1.25+303.2% | 0.67+191.3% | 0.42 | 0.51-50.5% |
| Funds from Operations | - | -1.99 | -8.52 | 22.96 | -7.92 | -9.49 | -8.36 | -9.79 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -13.50 | -13.57 | -8.72-193.0% | -7.22 | -7.27 | -15.08 | 9.38-88.8% |
| Cash from Operating Activities | - | -15.49 | -22.10 | 14.24 | -15.13 | -16.76 | -23.44 | -0.41-100.6% |
| Capital Expenditures | - | 0.00 | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Purchase or Sale of Investments | - | -92.08-642.0% | -5.36-181.3% | 21.25 | -158.23-746.1% | 16.99+231.8% | 6.59-61.9% | -6.70 |
| Purchase of Investments | - | -145.84 | -62.96 | -11.55 | -180.93 | -17.51 | -19.85 | -40.90 |
| Sale Or Maturity of Investments | - | 53.76+55.8% | 57.60+117.9% | 32.80-4.1% | 22.70-42.1% | 34.50-5.0% | 26.43+25.9% | 34.20+82.9% |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | -92.08-642.0% | -5.38-181.6% | 21.22 | -158.27-746.3% | 16.99+232.5% | 6.59-61.8% | -6.70 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 108.73+30102.8% | 0.15-92.2% | 0.46-97.3% | 171.93 | 0.36-97.1% | 1.92 | 17.00+85.0% |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 108.73+30102.8% | 0.15-92.2% | 0.46-97.3% | 171.93 | 0.36-97.1% | 1.92 | 17.00+85.0% |
| Proceedsfrom Stock Options | - | 0.42-78.1% | 0.00 | -1.92 | 123.60 | 1.92-84.6% | 0.00 | -12.45 |
| Issuance or Reduction of Debt, Net | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | - | 108.73+30102.8% | 0.15-92.2% | 0.46-97.3% | 171.93 | 0.36-97.1% | 1.92 | 17.00+85.0% |
| Net Change in Cash | - | 1.17+98.3% | -27.33 | 35.92+263.2% | -1.47-115.9% | 0.59+28.3% | -14.93 | 9.89 |
| Free Cash Flow | - | -15.49 | -22.12 | 14.21 | -15.18 | -16.76 | -23.44 | -0.41-100.6% |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Pharmaceutical Preparations | 28.52 | 72.30 | +153.5% | 100.0% |
| Total | 28.52 | 72.30 | +153.5% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 28.52 | 72.30 | +153.5% | 100.0% |
| Total | 28.52 | 72.30 | +153.5% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 23.69% | 3.0M | 12.8M | 289.53K |
| 2026-10-15 | 22.76% | 2.9M | 12.8M | 284.89K |
| 2026-09-30 | 19.34% | 2.8M | 14.6M | 268.56K |
| 2026-09-15 | 14.36% | 2.1M | 14.6M | 258.97K |
| 2026-08-31 | 16.56% | 2.1M | 12.8M | 236.70K |
| 2026-08-14 | 18.08% | 2.3M | 12.8M | 219.07K |
| 2026-07-31 | 18.73% | 2.3M | 12.5M | 208.86K |
| 2026-07-15 | 18.54% | 2.3M | 12.5M | 201.65K |
| 2026-06-30 | 19.31% | 2.4M | 12.5M | 189.90K |
| 2026-06-15 | 14.96% | 1.9M | 12.5M | 140.64K |
| 2026-05-29 | 13.50% | 1.7M | 12.5M | 120.88K |
| 2026-05-15 | 14.72% | 1.5M | 10.5M | 107.82K |
| 2026-04-30 | 15.05% | 1.6M | 10.4M | 94.47K |
| 2026-04-15 | 14.82% | 1.5M | 10.3M | 95.84K |
| 2026-03-31 | 14.57% | 1.5M | 10.5M | 97.35K |
| 2026-03-13 | 14.46% | 1.5M | 10.5M | 117.41K |
| 2026-02-27 | 14.10% | 1.5M | 10.5M | 119.72K |
| 2026-02-13 | 14.16% | 1.5M | 10.5M | 124.51K |
| 2026-01-30 | 15.41% | 1.5M | 10.0M | 128.24K |
| 2026-01-15 | 15.68% | 1.6M | 10.0M | 131.24K |
Option chain
Expiry 2026-11-20 · underlying 20.18, quoted 12 Nov 15:59 ET · ATM 20.00
Option quotes 12 Nov 14:30 ET. A date on a row is older than the last session (12 Nov). 14 rows.
Implied move 25.02% into expiry (call 2.600 + put 2.450 = 5.050 on 20.18)
Put/call open interest 0.13 (109 puts / 859 calls) · Put/call volume 0.05 (10 puts / 200 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 1 Jan | 15.00 | ITM | 3.00 | 7.50 | 0.00 | 0.00 | 441.4% -298.9 | 0 | 0 | 0 | 0.793 | -0.400 | 0.008 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 740.4% 0.0 | 0 | 0 | 0 | -0.207 | -0.398 | 0.008 | |
| call 1 Jan | 17.50 | ITM | 0.55 | 4.90 | 0.00 | 0.00 | 310.4% -266.1 | 0 | 0 | 0 | 0.723 | -0.365 | 0.010 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 576.8% 0.0 | 0 | 0 | 0 | -0.277 | -0.363 | 0.010 | |
| call 19 Oct | 20.00 | ATM | 0.30 | 4.90 | 1.70 | 0.00 | 415.4% -9.7 | 225 | 0 | 0 | 0.628 | -0.304 | 0.011 |
| put | ATM | 0.00 | 4.90 | 0.90 | -0.70 | 433.0% +8.0 | 75 | 10 | 10 | -0.372 | -0.302 | 0.011 | |
| call 21 Oct | 22.50 | OTM | 0.00 | 4.90 | 1.55 | 0.00 | 490.5% 0.0 | 271 | 0 | 0 | 0.583 | -0.362 | 0.012 |
| put 12 Oct | ITM | 0.50 | 4.90 | 1.95 | 0.00 | 294.1% -196.4 | 24 | 0 | 0 | -0.417 | -0.360 | 0.012 | |
| call 19 Oct | 25.00 | OTM | 0.00 | 4.90 | 0.45 | 0.00 | 550.1% 0.0 | 19 | 0 | 0 | 0.555 | -0.411 | 0.012 |
| put 5 Nov | ITM | 2.50 | 6.80 | 3.10 | 0.00 | 302.4% -247.4 | 8 | 0 | 0 | -0.445 | -0.408 | 0.012 | |
| call | 30.00 | OTM | 0.00 | 4.80 | 0.15 | -0.35 | 633.5% 0.0 | 300 | 200 | 100 | 0.515 | -0.477 | 0.012 |
| put 30 Sep | ITM | 7.50 | 12.00 | 6.54 | 0.00 | 409.8% -223.5 | 2 | 0 | 0 | -0.485 | -0.474 | 0.012 | |
| call 20 Oct | 35.00 | OTM | 0.00 | 4.90 | 0.35 | 0.00 | 703.4% 0.0 | 43 | 0 | 0 | 0.493 | -0.530 | 0.012 |
| put 1 Jan | ITM | 12.50 | 16.90 | 0.00 | 0.00 | 468.1% -235.3 | 0 | 0 | 0 | -0.507 | -0.526 | 0.012 | |
| call 13 Oct | 40.00 | OTM | 0.00 | 4.90 | 0.40 | 0.00 | 739.7% 0.0 | 1 | 0 | 0 | 0.478 | -0.568 | 0.012 |
| put 1 Jan | ITM | 17.50 | 21.90 | 0.00 | 0.00 | 522.2% -237.6 | 0 | 0 | 0 | -0.523 | -0.567 | 0.012 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-30 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-30 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-30 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-30 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-30 | SEC |
| 2026-11-02 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-02 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-02 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-20 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-14 | 8-K/A | 2026-08-13 | SEC | |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-13 | SCHEDULE 13G/A | SEC | ||
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-04 | SCHEDULE 13G/A | SEC | ||
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-29 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-29 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-04 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-29 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-29 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-29 | SEC |
| 2026-06-05 | 8-K | Current report | 2026-06-04 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 237.65K | 4 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 674 | 1 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 14.01K | 2 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| GILEAD SCIENCES, INC. | 24.44% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 8.10% |
| Paradigm Biocapital Advisors LP | 7.84% |
| Commodore Capital LP | 7.14% |
| RA CAPITAL MANAGEMENT, L.P. | 5.15% |
| Jupiter Topco LLC | 4.29% |
| BlackRock, Inc. | 3.87% |
| Parkman Healthcare Partners LLC | 3.64% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.82% |
| STATE STREET CORP | 2.75% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.09% |
| iShares Russell 2000 ETF | 1.24% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.67% |
| abrdn Healthcare Investors | 0.65% |
| Fidelity Small Cap Index Fund | 0.54% |
| iShares Russell 2000 Value ETF | 0.45% |
| abrdn Life Sciences Investors | 0.39% |
| Fidelity Extended Market Index Fund | 0.28% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.28% |
| Franklin Biotechnology Discovery Fund | 0.22% |
OakChart. ASMB. Cached 15 minutes. Terms